GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the "Company” or "ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect.".
Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 1PM ET on October 30th. One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here.
The presentation will also be live-streamed at the following link: https://wsw.com/webcast/tep25/prph/1692576
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Source: ProPhase Labs, Inc.
